A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy

This is a Phase II, multicenter, open-label study. Eligible subjects who have completed the HSK39297-202 study will be enrolled.Starting dose is 200 mg QD.Dose may be increased to 300 mg QD after 8-12 weeks of stable 200 mg QD therapy if 24-h urine protein excretion (UPE) remains \>1 g/24 h and no Grade ≥3 treatment-related adverse events (AEs) occur.After the treatment period, subjects will enter the 4-week safety follow-up period.

NCT Number	NCT07616700
Lead Sponsor	Haisco Pharmaceutical Group Co., Ltd.
Conditions	IgA Nephropathy (IgAN)
Enrollment	73 participants
Start Date	2025-08-25
Primary Completion	2026-12-05 (estimated)
Study Completion	2026-12-26 (estimated)
Updated on ClinicalTrials.gov	2026-06-01